IRDOpus Genetics, Inc.
Price
+119%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growth fading, the market with it.
Charts
As reported to the SEC, without any scoring.
Opus Genetics, Inc. (IRD) reported revenue of $755K in Q2 2026 (quarter ended Jun 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $8.1M. For the full year FY2025, revenue was $14M (+29% year on year) and net income −$50M. The next results filing is expected around Nov 11, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 11, 2026OPGx-BEST1 Gene Therapy Phase 1/2 Study Low Dose Cohort 1 3-month.Regulation FD disclosure · press release
- Sep 9, 2026On September 9, 2026, the Company shared 3- and 6-month results from the low-dose Cohort 1 of BIRD-1, the Company’s ongoing Phase 1/2 clinical trial of OPGx-BEST1 in patients with BEST1-related retinal diseases, including BVMD and ARB. Cohort 1 enrolled five participants treated at 1.5 x 10⁹ vg/eye: three participants …Regulation FD disclosure · Form 8-K
- Aug 6, 2026Opus Genetics Announces Financial Results for.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.